FLT3–ITD mutations are present in approximately 20% of acute myeloid leukemia (AML) cases, and they are associated with leukocytosis, an increased risk of relapse, and a shorter overall survival (OS) [1,2,3,4,5,6,7]. This evidence concerns the gene FLT3 and Increased total leukocyte count.